Ferilnic nirate produces delayed preconditioning against myocardial ischemia and reperfusion injury in rats

Arch Pharm Res. 2010 Jun;33(6):881-7. doi: 10.1007/s12272-010-0611-9. Epub 2010 Jul 6.

Abstract

To determine whether ferilnic nirate (FLNT) can precondition the rat heart against myocardial ischemia/reperfusion (I/R) damage and its mechanism, two groups of experiments were conducted. In the first group of experiments, rats were divided among four treatment groups: sham group; solvent with I/R (I/R control group); FLNT pretreatment with I/R (I/R FLNT group); and late ischemic preconditioning group (LPC group). In the second group of experiments without I/R, rats were divided into two treatment groups: control group and FLNT group. The results indicated that myocardial infarct size and the levels of creatine kinase and lactate dehydrogenase in the sera of the I/R FLNT group were significantly lower and the level of nitric oxide molecule and Mn-containing superoxide dismutase were significantly elevated in the heart tissue compared with I/R control group. The protein expression ratio of Bcl-2/Bax in heart tissue was significantly elevated in the I/R FLNT group. These results demonstrate FLNT is able to precondition rat hearts against myocardial ischemia/reperfusion damage to a similar level as that achieved via the late phase of ischemic preconditioning. The mechanism may involve the up-regulation of nitric oxide and the strengthening of anti-oxidant and anti-apoptosis cellular functions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Coumaric Acids / pharmacology
  • Coumaric Acids / therapeutic use*
  • Heart / drug effects
  • Hemodynamics / drug effects
  • Ischemic Preconditioning, Myocardial*
  • Male
  • Malondialdehyde / metabolism
  • Myocardial Infarction / pathology
  • Myocardial Ischemia / blood
  • Myocardial Ischemia / prevention & control*
  • Myocardial Reperfusion Injury / blood
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / enzymology
  • Myocardium / metabolism
  • Nitrates / pharmacology
  • Nitrates / therapeutic use*
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Protective Agents / pharmacology
  • Protective Agents / therapeutic use*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Superoxide Dismutase / metabolism
  • Time Factors
  • bcl-2-Associated X Protein / metabolism

Substances

  • Bax protein, rat
  • Biomarkers
  • Coumaric Acids
  • N-2-(ferulamidoethyl)nitrate
  • Nitrates
  • Protective Agents
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Nitric Oxide
  • Malondialdehyde
  • Nitric Oxide Synthase Type II
  • Superoxide Dismutase